Informação sobre produto
- (R)-2-((R)-6,7-Dimethoxy-1-(4-(Trifluoromethyl)Phenethyl)-3,4-Dihydroisoquinolin-2(1H)-Yl)-N-Methyl-2-Phenylacetamide
- (αR,1S)-3,4-Dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-2(1H)-isoquinolineacetamide
- 2(1H)-Isoquinolineacetamide, 3,4-dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-, (αR,1S)-
- Act-078573
- Act-078573(R)-2-((R)-6,7-dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide
Almorexant is a pharmacological agent that is used to treat insomnia. It is an orexin receptor antagonist and has been approved for the treatment of chronic insomnia in adults. Almorexant binds to the α1 subunit of the orexin receptors, which are located in the hypothalamus and have been shown to be involved in energy metabolism, locomotor activity, and sleep regulation. This drug inhibits neuronal excitation by blocking these receptors and can reduce wakefulness-promoting signaling. In humans, almorexant has been shown to produce a concentration-dependent decrease in wakefulness and increased sleep time when given at doses of 0.5mg or 1mg. Almorexant also has a significant effect on locomotor activity in animals with no effect on energy metabolism or body temperature.
Propriedades químicas
Consulta técnica sobre: 3D-FA103508 Almorexant
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.